Recent 8-K filings for RPID

• May 19, 2026 21:13 UTC other_material materiality 0.70 neutral item 1.01item 9.01

  RPID raises ~$9M in underwritten common stock and warrant offering; insiders add $140K

  Underwritten offering of 3.58M units (share + two warrants) at $1.955/unit; net proceeds ~$8.9M.

• May 13, 2026 20:33 UTC earnings materiality 0.65 negative item 2.02item 9.01

  Rapid Micro Biosystems Q1 revenue up 11% to $8.0M; net loss widens to $14.3M

  Total revenue $8.0M (+11% YoY); product revenue $5.6M (+36%).

• Mar 27, 2026 23:59 UTC leadership materiality 0.50 neutral item 5.02item 9.01

  COO John Wilson departs April 10; CEO Spignesi assumes operating role

  John Wilson, COO, will leave as of April 10, 2026 for family reasons; no disagreement with the Company.

• Mar 12, 2026 23:59 UTC earnings materiality 0.80 positive item 2.02item 7.01item 9.01

  Rapid Micro reports record Q4 revenue $11.3M (+37% YoY); 2026 guidance $37-41M; Samsung Biologics expands Growth Direct

  Q4 total revenue $11.3M (+37% YoY); product revenue $9.3M (+78%).

• Jan 13, 2026 23:59 UTC earnings materiality 0.75 positive item 2.02item 9.01

  Rapid Micro Biosystems pre-announces record Q4 rev $11.3M (+37% YoY); FY rev $33.6M (+20%)

  Q4 2025 total revenue expected ~$11.3M, up ~37% YoY; record multi-system order from Top 20 biopharma customer.

• Nov 07, 2025 23:59 UTC earnings materiality 0.75 positive item 2.02item 9.01

  Rapid Micro Biosystems Q3 revenue $7.8M (+3% YoY); raises FY guidance after record multi-system order

  Q3 2025 revenue $7.8M (+3% YoY); recurring revenue up 32% to $4.8M on record consumables.

• Aug 12, 2025 23:59 UTC debt materiality 0.75 positive item 1.01item 2.02item 2.03item 3.02item 7.01item 9.01

  Rapid Micro Biosystems Q2 revenue $7.3M (+10% YoY); enters $45M term loan with Trinity Capital

  Q2 2025 revenue $7.3M, up 10% YoY; net loss $11.9M ($0.27/sh) vs $12.6M ($0.29) prior year.

• Jun 17, 2025 23:59 UTC other_material materiality 0.55 neutral item 8.01item 9.01

  CEO Robert Spignesi diagnosed with treatable lymphoma; will continue to lead company

  CEO Robert Spignesi disclosed a recent diagnosis of a treatable form of lymphoma.

• May 23, 2025 23:59 UTC leadership materiality 0.30 neutral item 5.02item 5.07

  Director Jeffrey Schwartz resigns from Rapid Micro Biosystems board effective May 22, 2025

  Jeffrey Schwartz resigned as director and chair of nominating and corporate governance committee; not due to any disagreement.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

4 positive 1 negative 4 neutral

source · RPID on sec.gov